- My Forums
- Tiger Rant
- LSU Recruiting
- SEC Rant
- Saints Talk
- Pelicans Talk
- More Sports Board
- Fantasy Sports
- Golf Board
- Soccer Board
- O-T Lounge
- Tech Board
- Home/Garden Board
- Outdoor Board
- Health/Fitness Board
- Movie/TV Board
- Book Board
- Music Board
- Political Talk
- Money Talk
- Fark Board
- Gaming Board
- Travel Board
- Food/Drink Board
- Ticket Exchange
- TD Help Board
Customize My Forums- View All Forums
- Show Left Links
- Topic Sort Options
- Trending Topics
- Recent Topics
- Active Topics
Started By
Message
2
Posted on 1/15/19 at 7:38 pm to MSTiger33
I always screw these things up is my concern. I enter stocks ok these days but my exits always suck. i'm either way too early or too late.
Posted on 1/18/19 at 8:18 am to MSTiger33
Just some more publicity here. I'm not a subscriber.
LINK /
quote:
Allergan (AGN) is appealing to the Supreme Court in an effort to stall generic competition to its best-selling dry-eye drug Restasis. But the pharma giant also faces a threat on a different front: a small Canadian drug maker advancing its own medicine that could prove superior to Restasis.
The experimental dry-eye medicine is called VOS, a shorthand moniker for voclosporin ophthalmic solution. It’s being developed by Aurinia Pharmaceuticals (AUPH), a drug maker based in Victoria, the capital of British Columbia located on the southern tip of Vancouver Island.
LINK /
This post was edited on 1/18/19 at 8:20 am
Page 1 of 1
Popular
Back to top
Follow TigerDroppings for LSU Football News